Soluble B7-H1: Differences in production between dendritic cells and T cells

Xavier Frigola; Brant A. Inman; Christopher J. Krco; Xin Liu; Susan M. Harrington; Peggy A. Bulur; Allan B. Dietz; Haidong Dong; Eugene D. Kwon

doi:10.1016/j.imlet.2011.11.001

Soluble B7-H1: Differences in production between dendritic cells and T cells

Xavier Frigola, Brant A. Inman, Christopher J. Krco, Xin Liu, Susan M. Harrington, Peggy A. Bulur, Allan B. Dietz, Haidong Dong, Eugene D. Kwon

Research output: Contribution to journal › Letter › peer-review

67 Scopus citations

Abstract

Tumor cells aberrantly express several T cell inhibitory molecules including members of the B7-H co-regulatory family. Presumably tumor-expressed B7-H1 and B7-H3 confer resistance to elimination by the immune system. In addition, elevated levels of soluble B7-H1 (sB7-H1) has been identified in the sera of cancer patients, including renal carcinoma patients and is associated with increased cancer related death. Here we report that sB7-H1 is produced and released by activated mature dendritic cells (mDC). Immature DC, macrophages, monocytes, or T cells are refractory to releasing sB7-H1. Exposure of CD4+ and CD8+ T cells to mDC-derived sB7-H1 molecules induced apoptosis. These data suggest that the immunobiology of B7-H1 is perhaps more complex than previously thought. sB7-H1 molecules may represent an unanticipated contributing factor to immune homeostasis. That both immune and tumor cells can be sources of sB7-H1 suggests that optimization of co-regulatory blockade immunotherapy for solid malignancies of necessity will require impact of targeting tumor and immune-derived B7-H1 molecules.

Original language	English (US)
Pages (from-to)	78-82
Number of pages	5
Journal	Immunology Letters
Volume	142
Issue number	1-2
DOIs	https://doi.org/10.1016/j.imlet.2011.11.001
State	Published - Feb 29 2012

Keywords

B7-H1
Coregulatory
Dendritic cell
Soluble
T cell
Tumor cell

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.imlet.2011.11.001

Cite this

@article{2918ed8d7e0c4f1bb40c8450d8152620,

title = "Soluble B7-H1: Differences in production between dendritic cells and T cells",

abstract = "Tumor cells aberrantly express several T cell inhibitory molecules including members of the B7-H co-regulatory family. Presumably tumor-expressed B7-H1 and B7-H3 confer resistance to elimination by the immune system. In addition, elevated levels of soluble B7-H1 (sB7-H1) has been identified in the sera of cancer patients, including renal carcinoma patients and is associated with increased cancer related death. Here we report that sB7-H1 is produced and released by activated mature dendritic cells (mDC). Immature DC, macrophages, monocytes, or T cells are refractory to releasing sB7-H1. Exposure of CD4+ and CD8+ T cells to mDC-derived sB7-H1 molecules induced apoptosis. These data suggest that the immunobiology of B7-H1 is perhaps more complex than previously thought. sB7-H1 molecules may represent an unanticipated contributing factor to immune homeostasis. That both immune and tumor cells can be sources of sB7-H1 suggests that optimization of co-regulatory blockade immunotherapy for solid malignancies of necessity will require impact of targeting tumor and immune-derived B7-H1 molecules.",

keywords = "B7-H1, Coregulatory, Dendritic cell, Soluble, T cell, Tumor cell",

author = "Xavier Frigola and Inman, {Brant A.} and Krco, {Christopher J.} and Xin Liu and Harrington, {Susan M.} and Bulur, {Peggy A.} and Dietz, {Allan B.} and Haidong Dong and Kwon, {Eugene D.}",

note = "Funding Information: We thank Kim Harris and Noemi Vidal-Folch for technical help. Support for this work was provided by NIH/NCI grant CA134345 as well as generous support from The Richard M. Schulze Family Foundation (EDK), the Mayo Clinic Comprehensive Cancer Center and the Mayo Junior Faculty Development Award (HD).",

year = "2012",

month = feb,

day = "29",

doi = "10.1016/j.imlet.2011.11.001",

language = "English (US)",

volume = "142",

pages = "78--82",

journal = "Immunology Letters",

issn = "0165-2478",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Soluble B7-H1

T2 - Differences in production between dendritic cells and T cells

AU - Frigola, Xavier

AU - Inman, Brant A.

AU - Krco, Christopher J.

AU - Liu, Xin

AU - Harrington, Susan M.

AU - Bulur, Peggy A.

AU - Dietz, Allan B.

AU - Dong, Haidong

AU - Kwon, Eugene D.

N1 - Funding Information: We thank Kim Harris and Noemi Vidal-Folch for technical help. Support for this work was provided by NIH/NCI grant CA134345 as well as generous support from The Richard M. Schulze Family Foundation (EDK), the Mayo Clinic Comprehensive Cancer Center and the Mayo Junior Faculty Development Award (HD).

PY - 2012/2/29

Y1 - 2012/2/29

N2 - Tumor cells aberrantly express several T cell inhibitory molecules including members of the B7-H co-regulatory family. Presumably tumor-expressed B7-H1 and B7-H3 confer resistance to elimination by the immune system. In addition, elevated levels of soluble B7-H1 (sB7-H1) has been identified in the sera of cancer patients, including renal carcinoma patients and is associated with increased cancer related death. Here we report that sB7-H1 is produced and released by activated mature dendritic cells (mDC). Immature DC, macrophages, monocytes, or T cells are refractory to releasing sB7-H1. Exposure of CD4+ and CD8+ T cells to mDC-derived sB7-H1 molecules induced apoptosis. These data suggest that the immunobiology of B7-H1 is perhaps more complex than previously thought. sB7-H1 molecules may represent an unanticipated contributing factor to immune homeostasis. That both immune and tumor cells can be sources of sB7-H1 suggests that optimization of co-regulatory blockade immunotherapy for solid malignancies of necessity will require impact of targeting tumor and immune-derived B7-H1 molecules.

AB - Tumor cells aberrantly express several T cell inhibitory molecules including members of the B7-H co-regulatory family. Presumably tumor-expressed B7-H1 and B7-H3 confer resistance to elimination by the immune system. In addition, elevated levels of soluble B7-H1 (sB7-H1) has been identified in the sera of cancer patients, including renal carcinoma patients and is associated with increased cancer related death. Here we report that sB7-H1 is produced and released by activated mature dendritic cells (mDC). Immature DC, macrophages, monocytes, or T cells are refractory to releasing sB7-H1. Exposure of CD4+ and CD8+ T cells to mDC-derived sB7-H1 molecules induced apoptosis. These data suggest that the immunobiology of B7-H1 is perhaps more complex than previously thought. sB7-H1 molecules may represent an unanticipated contributing factor to immune homeostasis. That both immune and tumor cells can be sources of sB7-H1 suggests that optimization of co-regulatory blockade immunotherapy for solid malignancies of necessity will require impact of targeting tumor and immune-derived B7-H1 molecules.

KW - B7-H1

KW - Coregulatory

KW - Dendritic cell

KW - Soluble

KW - T cell

KW - Tumor cell

UR - http://www.scopus.com/inward/record.url?scp=84857194083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857194083&partnerID=8YFLogxK

U2 - 10.1016/j.imlet.2011.11.001

DO - 10.1016/j.imlet.2011.11.001

M3 - Letter

C2 - 22138406

AN - SCOPUS:84857194083

SN - 0165-2478

VL - 142

SP - 78

EP - 82

JO - Immunology Letters

JF - Immunology Letters

IS - 1-2

ER -

Soluble B7-H1: Differences in production between dendritic cells and T cells

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this